
Going forward, the Lundbeck Foundation, which is the majority stakeholder in pharmaceutical firm Lundbeck, will bet exclusively on Danish biotech companies, CEO at the Lundbeck Foundation Lene Skole tells Danish media Finans.
Specifically, the foundation will be merging its two funds, Ventures and Emerge, into one unit, dubbed Lundbeckfonden Biocapital.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app